Neurogene stockholders elect directors, approve executive compensation, ratify Deloitte

Neurogene Inc.

Class III directors Robert Baffi (9,540,734 for) and Rohan Palekar (10,058,331 for) elected to three-year terms.
Non-binding advisory vote on named executive officer compensation passed: 9,991,445 for, 36,394 against.
Ratification of Deloitte & Touche as auditor for FY 2026 approved: 9,345,925 for, 1,939,039 against.
Advisory vote on frequency of future compensation votes: 10,006,265 chose one year; company will hold votes annually.
Quorum of 11,387,407 shares (72.92%) present; meeting held June 3, 2026.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Neurogene Inc. shareholders approved Approval on an advisory (non-binding) basis of the compensation of the Company’s named executive officers at the 2026-06-03 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-03

Exact text from the filing

Approval on an advisory (non-binding) basis of the compensation of the Company’s named executive officers: Shares For Shares Against Shares Abstaining Broker Non-Votes 9,991,445 36,394 61,631 1,297,937

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Neurogene Inc. shareholders approved Election of two Class III directors, Robert Baffi and Rohan Palekar at the 2026-06-03 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-03

Exact text from the filing

Election of two Class III directors, Robert Baffi and Rohan Palekar, each to serve until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified: Nominee Shares For Shares Withheld Broker Non-Votes Robert Baffi 9,540,734 548,736 1,297,937 Rohan Palekar 10,058,331 31,139 1,293,937

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Neurogene Inc. shareholders approved Ratification on an advisory (non-binding) basis of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-03 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-03

Exact text from the filing

Ratification on an advisory (non-binding) basis of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026: Shares For Shares Against Shares Abstaining 9,345,925 1,939,039 102,443

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Neurogene Inc. shareholders approved An advisory, non-binding vote on whether future non-binding advisory votes on the compensation paid by the Company to its named executive officers should be held every one, two or three years at the 2026-06-03 meeting.

Proposal: say on pay frequency
Outcome: passed
Meeting: 2026-06-03

Exact text from the filing

An advisory, non-binding vote on whether future non-binding advisory votes on the compensation paid by the Company to its named executive officers should be held every one, two or three years: One Year Two Years Three Years Shares Abstaining Broker Non-Votes 10,006,265 3,407 16,721 63,077 1,297,937

View on SEC.gov

1594 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Neurogene Inc. filing history →

Source: SEC EDGAR

accession 0001404644-26-000040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.